Early use of high-titer plasma may prevent severe COVID-19
January 7, 2021
Administering convalescent plasma that has high levels of antibodies against SARS-CoV-2 within the first 3 days of symptoms was associated with significantly lower chances of progression to severe COVID-19, new evidence demonstrates.
Experts debate wisdom of delaying second COVID-19 vaccine dose
January 5, 2021
Another proposed strategy to extend the current supply of COVID-19 vaccines to more Americans involves splitting the current dosage of the Moderna vaccine in half.
Complete blood count scoring can predict COVID-19 severity
December 30, 2020
COVID-19 produces specific alterations in circulating blood cells that can be detected by a routine hematology analyzer.
FDA grants emergency use for Moderna COVID-19 vaccine
December 19, 2020
“It’s incumbent upon all us healthcare professionals to put ourselves out there as supporting this vaccine and supporting people getting it.”
FDA OKs emergency use of Pfizer COVID-19 vaccine
December 12, 2020
“Vaccinating healthcare workers, in particular, will be a model for the general public.”
FDA safety alert: Face masks with metal can burn during MRI
December 9, 2020
Many face masks contain a nose wire or metal clip that helps the product conform to the face. Some masks contain metal nanoparticles, while others have coatings with silver or copper.
Biden chooses California Attorney General Xavier Becerra to head HHS
December 7, 2020
Although his public health experience is limited, he served on the Congressional Ways and Means Committee overseeing health-related issues.
PPE shortage crisis continues at most hospitals, survey shows
December 7, 2020
A majority of hospitals and health care facilities surveyed report operating according to “crisis standards of care.”
CDC shortens COVID-19 quarantine time to 10 or 7 days, with conditions
December 3, 2020
The residual risk is approximately 1%, with an upper limit of 10%, when people quarantine for 10 days. .
Moderna filing for FDA emergency COVID-19 vaccine approval, reports 94.1% efficacy
November 30, 2020
Vaccine efficacy remained consistent across different groups analyzed by age, race/ethnicity, and gender.